AstraZeneca PLC vs Novartis AG
μκ°μ λ°λ₯Έ μκ°μ΄μ‘ λΉκ΅
AstraZeneca PLC
$248.3B
μμ #59
Novartis AG
$267.3B
μμ #55
μκ°μ λ°λ₯Έ μκ°μ΄μ‘
μ£Όμ μκ°
- AstraZeneca PLCμ΄(κ°) 2020λ κΉμ§ Novartis AGμ(λ₯Ό) μΆμνμ΅λλ€
- Novartis AGμ΄(κ°) 2026λ κΉμ§ AstraZeneca PLCμ(λ₯Ό) μΆμνμ΅λλ€
μ°λλ³ λΉκ΅
| μ°λ | AstraZeneca PLC | Novartis AG | μ λ |
|---|---|---|---|
| 2026 | $248.3B | $267.3B | Novartis AG |
| 2025 | $282.2B | $227.3B | AstraZeneca PLC |
| 2024 | $196.9B | $177.6B | AstraZeneca PLC |
| 2023 | $198.1B | $163.8B | AstraZeneca PLC |
| 2022 | $195.3B | $146.3B | AstraZeneca PLC |
| 2021 | $163.9B | $134.5B | AstraZeneca PLC |
| 2020 | $136.9B | $134.7B | AstraZeneca PLC |
| 2019 | $132.8B | $142.4B | Novartis AG |
| 2018 | $97.9B | $110.8B | Novartis AG |
| 2017 | $85.9B | $104.0B | Novartis AG |
| 2016 | $64.5B | $89.6B | Novartis AG |
| 2015 | $76.6B | $100.4B | Novartis AG |
| 2014 | $76.2B | $103.4B | Novartis AG |
| 2013 | $61.7B | $76.6B | Novartis AG |
| 2012 | $46.3B | $59.2B | Novartis AG |
| 2011 | $42.7B | $52.5B | Novartis AG |
| 2010 | $40.3B | $51.1B | Novartis AG |
| 2009 | $38.9B | $50.7B | Novartis AG |
| 2008 | $32.3B | $44.5B | Novartis AG |
| 2007 | $32.3B | $50.6B | Novartis AG |
| 2006 | $39.1B | $55.9B | Novartis AG |
| 2005 | $34.5B | $53.9B | Novartis AG |
| 2004 | $25.2B | $43.8B | Novartis AG |
| 2003 | $32.9B | $42.0B | Novartis AG |
| 2002 | $23.4B | $36.9B | Novartis AG |
| 2001 | $30.5B | $43.1B | Novartis AG |
| 2000 | $33.1B | $50.7B | Novartis AG |
| 1999 | $25.7B | $40.7B | Novartis AG |
| 1998 | $27.2B | $46.3B | Novartis AG |
| 1997 | $21.4B | $40.1B | Novartis AG |
| 1996 | $16.3B | $24.5B | Novartis AG |
| 1995 | $11.1B | $16.9B | Novartis AG |